Company Overview
AgomAb Therapeutics NV operates as a clinical-stage biopharmaceutical entity dedicated to developing novel disease-modifying therapies specifically targeting immunology and inflammatory diseases. The company concentrates its research and development efforts on chronic fibrotic indications where unmet medical needs exist, aiming to provide advanced treatments for these complex conditions. AgomAb functions within the healthcare sector and specifically within the biotechnology industry, a domain characterized by high research intensity and significant capital requirements for product development. The company's current market capitalization stands at $573.16M, while its annual revenue is N/A, and it employs 57 individuals. These valuation and headcount figures indicate that AgomAb is a mid-sized, early-to-mid stage biotechnology firm that has secured a substantial asset base relative to its current sales, reflecting a business model that relies heavily on future product approvals rather than immediate revenue generation. The lack of reported revenue in the trailing twelve months underscores the clinical-stage nature of the enterprise, where resources are predominantly allocated to advancing the Ontunisertib (AGMB-129) pipeline rather than commercializing existing products.
Financial Health
The company reported revenue of N/A for the trailing twelve months, with a net income of $-72,265,000 and an EBITDA of $-54,430,000. The significant gap between the reported revenue of N/A and the substantial net loss of $-72,265,000 reveals a cost structure dominated by research, development, and operational expenses rather than cost of goods sold, which is typical for pre-commercial biotechnology firms. There is no reported free cash flow, indicating that the company is currently burning cash to fund its pipeline and operational activities rather than generating surplus liquidity from operations. The gross margin is reported as 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%; these figures collectively indicate that the company has not yet achieved commercial scale or profitability from sales, resulting in margins that reflect the transitional phase of the business. The company holds $171.46M in cash against a debt load of $1.54M, resulting in a debt-to-equity ratio of 0.82. This balance sheet configuration suggests a highly conservative financial position with minimal leverage, providing ample runway to support ongoing development efforts without the immediate pressure of significant debt servicing. The current ratio stands at 13.99, which indicates an exceptionally strong short-term liquidity position where current assets far exceed current liabilities. Return on Equity and Return on Assets are both listed as N/A, which reveals that management effectiveness cannot be measured by traditional return metrics due to the absence of net income and equity base relative to profits.
Valuation Assessment
The trailing P/E ratio is N/A, while the forward P/E is -6.23; the difference between these metrics implies that the market is pricing the stock based on future expectations rather than historical earnings, and the negative forward P/E suggests analysts anticipate a path to profitability or are extrapolating from a negative earnings baseline. The price-to-book ratio is -0.00, indicating that the market valuation does not align with the book value of the company in a traditional sense, often seen in biotechnology firms where intangible assets and pipeline value are not fully captured on the balance sheet. The price-to-sales ratio is N/A and the EV/EBITDA is -2.39; these alternative valuation metrics suggest that traditional multiples are not applicable, and the negative EV/EBITDA reflects the current cash burn and lack of earnings generation relative to enterprise value. The 52-week high is $17.45 and the 52-week low is $10.50; without a specific current price provided in the facts, the stock's position relative to this range cannot be calculated, but the range defines the recent trading volatility within a span of $6.95. The beta is N/A, which means there is no historical data available to quantify the stock's price volatility relative to the broader market, suggesting that its movements may be driven more by specific clinical trial results than general market sentiment.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, indicating that the company is not yet in a phase where historical growth rates can be calculated or compared. Because there is no revenue or earnings growth data, it is impossible to determine whether earnings are growing faster or slower than revenue, as both metrics are currently absent from the financial reporting. AgomAb is not a dividend payer, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%; consequently, the company reinvests all available earnings and cash reserves into research and development to advance its therapeutic pipeline rather than distributing income to shareholders. The overall growth and income profile is defined by a lack of current income generation and historical growth metrics, with the company's value proposition resting entirely on the potential future success of its clinical-stage assets.